Cancer clinical trials in the region Centre-Val de Loire

67 currently recruiting clinical trials
Region Centre-Val de Loire

Phase 2 Colon cancer Rectal cancer Anal cancer Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer #NCT06475352
Locally Advanced Metastatic None Systemic Treatment-Naive
Centre Hospitalier Régional d'Orléans Hôpital de La Source (Orléans), Centre Hospitalier Régional Universitaire de Tours (Tours)
UNICANCER
Phase 2 Lymphoma CLL & Richter's syndrome #NCT04963946
B cell lymphoma CLL (Chronic Lymphocytic Leukemia) Lymphocytic lymphoma > 60 ml/min 50-60 ml/min 30-50 ml/min None Systemic Treatment-Naive
Centre Hospitalier Régional d'Orléans Hôpital de La Source (Orléans), Centre Hospitalier Régional Universitaire de Tours (Tours)
French Innovative Leukemia Organisation (FILO)
Phase 2 Breast cancer #NCT04985266
HER2 Negative HR Positive Localized None Surgery Chemotherapy Hormone therapy
Targeted therapy
Centre Hospitalier de Blois (Blois)
Fiducie de la Fondation Royal Marsden NHS
Phase 2 Endometrial cancer #NCT03624244
Other Locally Advanced Metastatic None Surgery Hormone therapy
Centre Hospitalier Régional Universitaire de Tours (Tours)
Centre Léon Bérard
Phase 2 Colon cancer Rectal cancer #NCT04262687
Metastatic MSS None 1 Systemic Treatment-Naive Surgery Chemotherapy
MSI/dMMR Immunotherapy Immunotherapy
Polyclinique de Blois (La Chaussée-Saint-Victor), Centre Hospitalier Régional Universitaire de Tours (Tours)
Fédération Francophone de Cancérologie Digestive
Early Access Lymphoma
B cell lymphoma Large B cell lymphoma 1
Systemic Treatment-Naive
Hoffmann-La Roche
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR 1 Targeted therapy
Systemic Treatment-Naive
Janssen
Early Access Bladder / Urinary Tract / Urethral cancer
Invasive bladder cancer Urothelial carcinoma Locally Advanced Metastatic None Systemic Treatment-Naive
Merck Sharp & Dohme LLC
Early Access Stomach and esophageal cancer
Stomach Oesogastric junction Adenocarcinoma Locally Advanced Metastatic HER2 PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) None Systemic Treatment-Naive
Merck Sharp & Dohme LLC
Early Access Bladder / Urinary Tract / Urethral cancer
Invasive bladder cancer Urothelial carcinoma Locally Advanced Metastatic None Systemic Treatment-Naive
Astellas Pharma Développement mondial, Inc.